Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors

Ann N Y Acad Sci. 1996 Jan 17;777:399-403. doi: 10.1111/j.1749-6632.1996.tb34452.x.

Abstract

CDP-choline was given to patients with Alzheimer's disease (AD) at a daily dose of 1000 mg/day p.o. for one month. This compound slightly improved mental performance, tended to reduce theta activity in fronto-temporal regions, increasing alpha power in occipital areas, and enhanced cerebrovascular perfusion by increasing blood flow velocity and reducing pulsatility and resistance indexes. In addition, CDP-choline diminished histamine and interleukin-1 levels in blood and serum, respectively, and increased plasma TNF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / immunology
  • Alzheimer Disease / physiopathology
  • Alzheimer Disease / psychology
  • Brain Mapping*
  • Cerebrovascular Circulation / drug effects*
  • Cognition / drug effects*
  • Cytidine Diphosphate Choline / therapeutic use*
  • Cytokines / blood
  • Female
  • Hemodynamics / drug effects
  • Histamine / blood
  • Humans
  • Male
  • Middle Aged

Substances

  • Cytokines
  • Cytidine Diphosphate Choline
  • Histamine